Significance of non‐presynaptic SPECT tracer methods in Parkinson's disease
Identifieur interne : 003022 ( Istex/Corpus ); précédent : 003021; suivant : 003023Significance of non‐presynaptic SPECT tracer methods in Parkinson's disease
Auteurs : Klaus L. LeendersSource :
- Movement Disorders [ 0885-3185 ] ; 2003-10.
English descriptors
- KwdEn :
- HMPAO, IBZM, PET, Parkinson's disease, SPECT.
Abstract
Tropane‐related tracers for SPECT and PET scanning have shown their value in assessing the in vivo striatal presynaptic status of the dopaminergic neurotransmitter system in man. Previously, there were a few other tracers suggested to be useful in the study of in vivo brain biochemistry in humans, particularly in patients afflicted with Parkinson's disease (PD) or parkinsonian syndromes. We summarize the work concerning the two main tracers applied in that context using single photon emission tomography (SPECT) scanning in patients with PD: IBZM and HMPAO. IBZM binds specifically to striatal dopamine D2 receptors and HMPAO uptake is a measure of cerebral tissue perfusion. © 2003 Movement Disorder Society
Url:
DOI: 10.1002/mds.10577
Links to Exploration step
ISTEX:53B064B1181BC56EAFB11CDCE377DC7BE4C5B045Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Significance of non‐presynaptic SPECT tracer methods in Parkinson's disease</title><author><name sortKey="Leenders, Klaus L" sort="Leenders, Klaus L" uniqKey="Leenders K" first="Klaus L." last="Leenders">Klaus L. Leenders</name><affiliation><mods:affiliation>Department of Neurology, Groningen University Hospital, Groningen, The Netherlands</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:53B064B1181BC56EAFB11CDCE377DC7BE4C5B045</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1002/mds.10577</idno><idno type="url">https://api.istex.fr/document/53B064B1181BC56EAFB11CDCE377DC7BE4C5B045/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003022</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Significance of non‐presynaptic SPECT tracer methods in Parkinson's disease</title><author><name sortKey="Leenders, Klaus L" sort="Leenders, Klaus L" uniqKey="Leenders K" first="Klaus L." last="Leenders">Klaus L. Leenders</name><affiliation><mods:affiliation>Department of Neurology, Groningen University Hospital, Groningen, The Netherlands</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2003-10">2003-10</date><biblScope unit="vol">18</biblScope><biblScope unit="issue">S7</biblScope><biblScope unit="supplement">7</biblScope><biblScope unit="page" from="S39">S39</biblScope><biblScope unit="page" to="S42">S42</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">53B064B1181BC56EAFB11CDCE377DC7BE4C5B045</idno><idno type="DOI">10.1002/mds.10577</idno><idno type="ArticleID">MDS10577</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>HMPAO</term><term>IBZM</term><term>PET</term><term>Parkinson's disease</term><term>SPECT</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Tropane‐related tracers for SPECT and PET scanning have shown their value in assessing the in vivo striatal presynaptic status of the dopaminergic neurotransmitter system in man. Previously, there were a few other tracers suggested to be useful in the study of in vivo brain biochemistry in humans, particularly in patients afflicted with Parkinson's disease (PD) or parkinsonian syndromes. We summarize the work concerning the two main tracers applied in that context using single photon emission tomography (SPECT) scanning in patients with PD: IBZM and HMPAO. IBZM binds specifically to striatal dopamine D2 receptors and HMPAO uptake is a measure of cerebral tissue perfusion. © 2003 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Klaus L. Leenders MD, PhD</name><affiliations><json:string>Department of Neurology, Groningen University Hospital, Groningen, The Netherlands</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>SPECT</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>PET</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>IBZM</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>HMPAO</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Tropane‐related tracers for SPECT and PET scanning have shown their value in assessing the in vivo striatal presynaptic status of the dopaminergic neurotransmitter system in man. Previously, there were a few other tracers suggested to be useful in the study of in vivo brain biochemistry in humans, particularly in patients afflicted with Parkinson's disease (PD) or parkinsonian syndromes. We summarize the work concerning the two main tracers applied in that context using single photon emission tomography (SPECT) scanning in patients with PD: IBZM and HMPAO. IBZM binds specifically to striatal dopamine D2 receptors and HMPAO uptake is a measure of cerebral tissue perfusion. © 2003 Movement Disorder Society</abstract><qualityIndicators><score>3.971</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>713</abstractCharCount><pdfWordCount>2675</pdfWordCount><pdfCharCount>17368</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>108</abstractWordCount></qualityIndicators><title>Significance of non‐presynaptic SPECT tracer methods in Parkinson's disease</title><genre><json:string>Serial article</json:string></genre><host><volume>18</volume><pages><total>4</total><last>S42</last><first>S39</first></pages><issn><json:string>0885-3185</json:string></issn><issue>S7</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2003</publicationDate><copyrightDate>2003</copyrightDate><doi><json:string>10.1002/mds.10577</json:string></doi><id>53B064B1181BC56EAFB11CDCE377DC7BE4C5B045</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/53B064B1181BC56EAFB11CDCE377DC7BE4C5B045/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/53B064B1181BC56EAFB11CDCE377DC7BE4C5B045/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/53B064B1181BC56EAFB11CDCE377DC7BE4C5B045/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Significance of non‐presynaptic SPECT tracer methods in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2003</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Significance of non‐presynaptic SPECT tracer methods in Parkinson's disease</title><author><persName><forename type="first">Klaus L.</forename><surname>Leenders</surname><roleName type="degree">MD, PhD</roleName></persName><note type="correspondence"><p>Correspondence: Department of Neurology, Groningen University Hospital, Hanzeplein 1, 9700 RB Groningen, The Netherlands</p></note><affiliation>Department of Neurology, Groningen University Hospital, Groningen, The Netherlands</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2003-10"></date><biblScope unit="vol">18</biblScope><biblScope unit="issue">S7</biblScope><biblScope unit="supplement">7</biblScope><biblScope unit="page" from="S39">S39</biblScope><biblScope unit="page" to="S42">S42</biblScope></imprint></monogr><idno type="istex">53B064B1181BC56EAFB11CDCE377DC7BE4C5B045</idno><idno type="DOI">10.1002/mds.10577</idno><idno type="ArticleID">MDS10577</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2003</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Tropane‐related tracers for SPECT and PET scanning have shown their value in assessing the in vivo striatal presynaptic status of the dopaminergic neurotransmitter system in man. Previously, there were a few other tracers suggested to be useful in the study of in vivo brain biochemistry in humans, particularly in patients afflicted with Parkinson's disease (PD) or parkinsonian syndromes. We summarize the work concerning the two main tracers applied in that context using single photon emission tomography (SPECT) scanning in patients with PD: IBZM and HMPAO. IBZM binds specifically to striatal dopamine D2 receptors and HMPAO uptake is a measure of cerebral tissue perfusion. © 2003 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>SPECT</term></item><item><term>PET</term></item><item><term>Parkinson's disease</term></item><item><term>IBZM</term></item><item><term>HMPAO</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2003-10">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/53B064B1181BC56EAFB11CDCE377DC7BE4C5B045/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="105"><doi origin="wiley" registered="yes">10.1002/mds.v18:7+</doi><titleGroup><title type="supplementTitle">Dopamine Transporter Imaging</title></titleGroup><numberingGroup><numbering type="journalVolume" number="18">18</numbering><numbering type="journalIssue">S7</numbering><numbering type="supplement" number="7">7</numbering></numberingGroup><coverDate startDate="2003-10">October 2003</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="80" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.10577</doi><idGroup><id type="unit" value="MDS10577"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2003 Movement Disorder Society</copyright><eventGroup><event type="firstOnline" date="2003-09-26"></event><event type="publishedOnlineFinalForm" date="2003-09-26"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">S39</numbering><numbering type="pageLast">S42</numbering></numberingGroup><correspondenceTo>Department of Neurology, Groningen University Hospital, Hanzeplein 1, 9700 RB Groningen, The Netherlands</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS10577.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="37"></count><count type="wordTotal" number="2979"></count></countGroup><titleGroup><title type="main" xml:lang="en">Significance of non‐presynaptic SPECT tracer methods in Parkinson's disease</title><title type="short" xml:lang="en">IBZM and MPAO in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Klaus L.</givenNames><familyName>Leenders</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>k.l.leenders@neuro.azg.nl</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="NL" type="organization"><unparsedAffiliation>Department of Neurology, Groningen University Hospital, Groningen, The Netherlands</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">SPECT</keyword><keyword xml:id="kwd2">PET</keyword><keyword xml:id="kwd3">Parkinson's disease</keyword><keyword xml:id="kwd4">IBZM</keyword><keyword xml:id="kwd5">HMPAO</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Tropane‐related tracers for SPECT and PET scanning have shown their value in assessing the in vivo striatal presynaptic status of the dopaminergic neurotransmitter system in man. Previously, there were a few other tracers suggested to be useful in the study of in vivo brain biochemistry in humans, particularly in patients afflicted with Parkinson's disease (PD) or parkinsonian syndromes. We summarize the work concerning the two main tracers applied in that context using single photon emission tomography (SPECT) scanning in patients with PD: IBZM and HMPAO. IBZM binds specifically to striatal dopamine D<sub>2</sub> receptors and HMPAO uptake is a measure of cerebral tissue perfusion. © 2003 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Significance of non‐presynaptic SPECT tracer methods in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>IBZM and MPAO in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Significance of non‐presynaptic SPECT tracer methods in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Klaus L.</namePart><namePart type="family">Leenders</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Groningen University Hospital, Groningen, The Netherlands</affiliation><description>Correspondence: Department of Neurology, Groningen University Hospital, Hanzeplein 1, 9700 RB Groningen, The Netherlands</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2003-10</dateIssued><copyrightDate encoding="w3cdtf">2003</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">37</extent><extent unit="words">2979</extent></physicalDescription><abstract lang="en">Tropane‐related tracers for SPECT and PET scanning have shown their value in assessing the in vivo striatal presynaptic status of the dopaminergic neurotransmitter system in man. Previously, there were a few other tracers suggested to be useful in the study of in vivo brain biochemistry in humans, particularly in patients afflicted with Parkinson's disease (PD) or parkinsonian syndromes. We summarize the work concerning the two main tracers applied in that context using single photon emission tomography (SPECT) scanning in patients with PD: IBZM and HMPAO. IBZM binds specifically to striatal dopamine D2 receptors and HMPAO uptake is a measure of cerebral tissue perfusion. © 2003 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>SPECT</topic><topic>PET</topic><topic>Parkinson's disease</topic><topic>IBZM</topic><topic>HMPAO</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><detail type="issue"><caption>no.</caption><number>S7</number></detail><detail type="supplement"><caption>Suppl. no.</caption><number>7</number></detail><extent unit="pages"><start>S39</start><end>S42</end><total>4</total></extent></part></relatedItem><identifier type="istex">53B064B1181BC56EAFB11CDCE377DC7BE4C5B045</identifier><identifier type="DOI">10.1002/mds.10577</identifier><identifier type="ArticleID">MDS10577</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2003 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003022 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003022 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:53B064B1181BC56EAFB11CDCE377DC7BE4C5B045
|texte= Significance of non‐presynaptic SPECT tracer methods in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |